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ABSTRACT
Objectives: Mifepristone for first-trimester medical termination of pregnancy (MTOP) became avail-
able in Quebec in 2018, one year after the rest of Canada. Using the theory of the Diffusion of
Innovation (DOI) and the transtheoretical model of change (TTM), we investigated factors influenc-
ing the implementation of mifepristone MTOP in Quebec.
Material and Methods: Semi-structured interviews were conducted with 37 Quebec physicians in
early 2018. Deductive thematic analysis guided by the theory of DOI explored facilitators and bar-
riers to physicians’ adoption of mifepristone MTOP. We then classified participants into five stages
of mifepristone adoption based on the TTM. Follow-up data collection one year later assessed fur-
ther adoption.
Results: At baseline, three physicians provided mifepristone MTOP (Maintenance) and two were
about to start (Action). Thirteen physicians at Preparation and Advanced Contemplation stages
intended to start while, within the Slow Contemplation, two intended to start and ten were
unsure. Seven had no intention to provide mifepristone MTOP (Pre-Contemplation). Major reported
barriers were: complexity of local health care organisations, medical policy restrictions, lack of sup-
port, and general uncertainty. One year later, ten physicians provided mifepristone MTOP (includ-
ing three at baseline) and nine still intended to, while seventeen did not intend to start provision.
Seven of sixteen participants (44%) who worked in TOP clinics at baseline were still not providing
MTOP with mifepristone one year later.
Conclusion: Despite ideological support, mifepristone MTOP uptake in Quebec is slow and labori-
ous, mainly due to restrictive medical policies, vested interests in surgical provision and administra-
tive inertia.
Abbreviations: CART: Canadian Abortion Research Team; CART-Mife-Study: CART-Mifepristone
Implementation Study; CMQ: College of physicians of Quebec; DOI: Diffusion of innovation; FP:
Family physician; MIFE-MISO: Mifepristone-misoprostol combination; MTOP: Medical termination of
pregnancy; OB: Obstetrician-gynaecologist; T1 MTOP: First trimester medical termination of preg-
nancy; TOP: Termination of pregnancy; TTM: Transtheoretical model of change
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Introduction
In 2012, there were nearly 101,000 voluntary terminations
of pregnancy (TOP) reported in Canada, for a termination
rate of 14.1/1 000 women aged 15–44 years [1,2]. At that
time, most TOP were surgical (96%) [3], and medical termi-
nations of pregnancy (MTOP) were still performed using
methotrexate/misoprostol or misoprostol alone [4]. British
Columbia and Quebec were the only provinces where TOP
services were equally located in urban and rural areas [3].
Owing to a long history of feminists’ battles, favourable
policies and governmental support [5], Quebec has 49 pub-
lic TOP facilities, representing half of all facilities found in
Canada in 2012 [3]; TOP stigma and harassment is almost
nonexistent [3].) In July 2015 [6], more than 25 years after
France and China [4], Health Canada approved the mife-
pristone-misoprostol combination (MIFE-MISO) for first tri-
mester MTOP (T1 MTOP). It was believed that MIFE-MISO
would increase access to TOP care for all Canadian women
and offer them a new early TOP option. However, while
medication approval falls under federal jurisdiction, provin-
ces are responsible for the delivery of health care and may
impose their own restrictions. As seen in Table 1, Health
Canada’s initial approval was associated with several restric-
tions [7], two of which were in contradiction with existing
policies in Quebec. Following availability of MIFE-MISO in
Canada in January 2017 [8], Health Canada removed most
of its restrictions, including mandatory online MTOP
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training [9,10]. In December 2017, the College of physicians
of Quebec (CMQ), the regulatory body for medical practice
in Quebec, released its own guidelines, authorising avail-
ability of MIFE-MISO in Quebec (one year later than the
rest of Canada), with its own restrictions, including manda-
tory TOP clinical training for physicians not already provid-
ing TOP or curettage [11].
Adoption of a new behaviour such as a new clinical prac-
tice is often variable amongst individuals. As shown by
Prochaska and DiClemente with the transtheoretical model
of change (TTM) [12], people move through a series of
stages when modifying behaviour: Pre-Contemplation,
Contemplation, Preparation, Action and Maintenance. A sixth
stage may be added for Relapse [12]. The TTM recognises
change as a process that develops over time. In parallel,
Rogers’ theory of the Diffusion of Innovation (DOI)[13,14]
defines the adoption of innovation amongst individuals
within a social system on the basis of their innovativeness,
or in other words, on their rate of adoption of an innov-
ation, also divided into five categories comparable to those
of TTM. The theory of the DOI also provides constructs to
capture determinants (barriers and facilitators) for implemen-
tation of innovations in health service delivery and health
systems [14]. Given that prescribing MIFE-MISO for T1 MTOP
would be a new practice for most Canadian physicians, our
Contraception and Abortion Research Team (https://cart-
grac.ubc.ca/)[13,14] decided to perform a national study [15],
guided by Roger’s theory, to understand health policy,
system and service facilitators and barriers to the implemen-
tation of mifepristone MTOP practice in primary care.
Considering the particular situation of Quebec, CART
researchers in Quebec proposed a secondary study where
the specific barriers and facilitators of implementation of
MIFE-MISO T1 MTOP in Quebec were guided by the theory
of the DOI and classified using the TTM.
Methods
This study is embedded in a larger observational mixed-
methods programme of research, the CART-Mifepristone
Implementation Study (CART-Mife Study) [15]. We (EG &
MSW) performed and audiotaped 30–45min semi-structured
interviews in French with family physicians (FP) and obstetri-
cians-gynaecologists (OB) from all Health Regions in Quebec
between January and March 2018 (except for one interview
in mid-October 2017). Recruitment was performed amongst
members of various Quebec medical associations, partici-
pants to the quantitative component of the CART-Mife
Study, and members of a community of practice for MTOP
providers established for the CART-Mife Study (recruitment
strategy thoroughly described in a previous publication)
[16]. Nurse practitioners were not interviewed because CMQ
did not allow them to provide MIFE-MISO without supervi-
sion of physicians trained to provide MTOP (Table 1).
The development of the 14-question interview guide
[17] was based on Rogers’ theory [13] and its application in
Table 1. Changes of baseline restrictions of Health Canada (2015) [7,9,42] and the College of physicians of Quebec (2017)[11,25,43–45].
Topic
Health Canada baseline requirements
July 2015 Date of removal
College of physicians of Quebec baseline
requirements December 2017
Date of
removal
Observed ingestion Mifepristone must be taken in front
of the prescribing physicians
October 2016 Not required
Training Training and certification for
pharmacists [10]
May 2017 Not required
Training and certification for
prescribing physicians [9]
November 2017 Clinical training in surgical abortion;
modified in 2018 for Clinical training in
abortion (MA and/or surgical) for
physicians not already providing
abortion or curettage
Registration Registration of prescribers and
pharmacists with the manufacturer
November 2017 None – Forbidden by law [44]
Dispensing Dispensing directly to patients by
prescribing physicians
November 2017 None - Forbidden by law [44,45]
Prescribing Prescription by physicians only;
modified in 2017 to allow
prescribing by knowledgeable
healthcare professionals
November 2017 Prescription by physicians only; Modified
in 2018 for prescription by physicians
and nurse practitioners who practice
under the supervision of physicians
who have followed the required clinical
training in abortion
Consent Patient’s signature of a manufacturer
consent form
November 2017 Verbal consent and notification in
patient’s chart
Gestational age 49 days from last menstrual period;
modified in 2017 for 63 days
November 2017 63 days
Ultrasound Ultrasound dating to confirm
gestational age and rule out
ectopic pregnancy prior to
prescribing
April 2019 Ultrasound dating to confirm gestational
age and rule out ectopic pregnancy
prior to prescribing
Information sheet Information sheet with prescribing
physician’s contact information
given to the patient
May 2017 Information sheet with prescribing
physician’s contact information given
to the patient
May 2018
Declaration Not required Annual declaration of medical and/or
surgical abortion practice by
physicians to the College
May 2018
Record Not required Record all patients’ charts on medical
abortion with health insurance
number of patients, annually
May 2018
The training programme required for certification by Health Canada was provided by the Society of Obstetricians and Gynaecologists of Canada. [10] It is
still available to all professionals as an accredited continuous medical education programme. Online training programmes are not recognised as sufficient
to allow T1MA practice with mifepristone by the College of physicians of Quebec which requires a clinical traineeship in abortion during medical resi-
dency or in an accredited abortion clinic for untrained practicing physicians.
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organisations [14]. This interview guide allowed us to cap-
ture the complex process of implementation of an innov-
ation, on an individual and a system-wide basis. Key
constructs such as characteristics of the innovation and the
adopter, communication and influence, system antecedents
and readiness, outer context and implementation process
helped to generate evidence on the facilitators and barriers
faced by physicians in adopting the new behaviour.
Confidential transcription of the Quebec interviews took
place from April to October 2018 and thematic analysis
[18] from October 2018 to March 2019. Through iterative
reading, we (EG & MSW) separately organised the data into
various themes describing facilitators and barriers; then, we
compared our results for each theme and subtheme and
resolved discrepancies through discussion to ensure accur-
ate interpretation of the data. In parallel with the thematic
analysis, we categorised participants into the five TTM
stages defined by the characteristics in Table 2 [12].
Facilitators and barriers were compiled for each stage.
In April 2019, we invited participants to answer a 3-ques-
tion follow-up survey by phone or email regarding: 1) whether
or not they had adopted the new behaviour; 2) if they had
done so, for how many patients had they provided MIFE-
MISO T1 MTOP within the last year; and 3) if they had not
started, what was their intention in the future. We calculated
percentages and Chi square tests to compare participants
who provided MIFE-MISO T1 MTOP with those who did not.
Ethics approval was obtained from the Behavioural
Research Ethics Board of the University of British Columbia
and the BC Women’s Hospital and Health Centre,
Vancouver (CW16-01006).
Results
Interviews were conducted with 37 physicians (25 FP and
12 OB). Characteristics of participants have been described
in a previous publication [16]. In summary, 81% of partici-
pants were females; 46% were 50 years old or older; 43%
were working in public TOP clinics; 60% did not provide
either T1 MTOP or surgical TOP; and 14% had completed
the online MTOP training programme [10].
Baseline behaviour
The classification of participants according to TTM (Table 3)
showed that, at the time of interview, only three partici-
pants were providing MIFE-MISO (Maintenance stage), and
two were about to begin (Action stage). These five partici-
pants were already providing both medical and surgical
TOPs. All other participants (86%) were either at the
Preparation, Contemplation or Pre-Contemplation stages.
Facilitators
As shown with representative quotations in Table 4, at all
stages of change, participants were able to identify facilita-
tors to this practice, such as influence or support of col-
leagues (« … we turned to them [another clinic] to at least
have the mechanics and have an idea of how they worked
and now it’s sure that it will be available, we’re going to offer
it… » (QC-NTNP-18)), requests from patients and col-
leagues (« … women ask for it because they have heard
about it … » (QC-TP-2)), awareness of research and study
and interest in a new practice. In spite of these facilitators,
barriers to implementation were much more often dis-
cussed (Table 5).
Barriers
Complexity of local health care organisation
Complexity of local health care organisation (mostly
Centres integres de sante et de services sociaux which
include hospitals and community services in each region)
was mentioned by participants in all stages of the TTM. It
included lack of administrative will to provide the service,
confusion about the qualifications of physicians (FPs versus
OB) for provision of MIFE-MISO, possible lack of available
physicians because of administrative decisions, time-con-
suming approval of MIFE-MISO T1 MTOP protocol by mul-
tiple decision-making levels, difficulties in obtaining the
drug from hospital or community pharmacies, complex
drug distribution within the hospital, laborious access to
ultrasound dating, serum BhCG or curettage, and difficul-
ties in offering timely first visit and follow-up because of
scheduling challenges. As mentioned by one participant:
« … We had a plan, but since the announcement of avail-
ability in December, I made some contacts with pharmacists
in my hospital, I made contacts with my immediate superiors
because I work in a health care organisation and, there, it is
quite nebulous and not easy and I had an email telling me
that no offer of medication should be made as long as we
did not have structured directives from a committee that
should be set up soon.» (QC-NTNP-18)
Lack of local resources and support of colleagues
Lack of local resources and support of colleagues, and
uncertainty about such resources were frequently reported
Table 2. Description of participants according to the each stage of
change [12].
Stage of
change (TTM) Description of participant
Maintenance Those who had started the practice of MIFE-MISO
T1MA at least a few weeks before the
interview, regardless of the facilitators or
barriers they had faced
Action Those who had the intention to provide MIFE-
MISO T1MA services, had prepared all the
necessary material (evaluation form, consent
form, protocol, etc.) and were ready to start
Preparation Those who had the intention to provide MIFE-
MISO T1MA and had either followed the SOGC
T1MA training programme OR were preparing
all the material to be able to start but were
not yet ready to start
Contemplation
Advanced Those who had the intention to provide MIFE-
MISO T1MA and did not follow the SOGC
T1MA training programme AND were either
potentially preparing material OR were actual
surgical abortion providers
Slow Those who did not follow the SOGC T1MA
training programme and were, either not sure
of their intention in providing MIFE-MISO
T1MA, OR if they intended to, were not yet
preparing any material to offer this service
Pre-Contemplation Those who did not follow the SOGC T1MA
training programme and did not have the
intention to provide MIFE-MISO T1MA
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by participants in the Preparation and Contemplation
stages. Health managers were said to be reluctant to accel-
erate the process of implementation; participants did not
have receptionists and/or counsellors to help them;
there were not enough nurses working in their medical
clinics (« We only have two and a half nurses working with
us ( 20 family physicians)… who help doctors make
adapted access. So it’s not a lot of staff to assist the doctor,
answer questions, answer the phone or transfer situations to
us that would be problematic. » (QC-NTNP-23)); nurses had
precarious working status or were exhausted; FP did not
have the support of OB and vice-versa; some participants
felt they were left on their own to organise MTOP care;
some of their colleagues were against provision of MTOP
to preserve existing services; and some OB refused to take
care of MTOP complications.
Confusion on practice policies
Confusion and uncertainty about practice policies from the
CMQ were mentioned in all stages, and was reported as
one of the major barriers at the Action, Preparation and
Advanced Contemplation stages. While some participants
were unaware of these policies, others were confused, such
as this physician: « … what I saw from the College des
medecins, was that they, in terms of online training, they
didn’t seem to be too much for that; maybe, I was wrong,
they say that it would take doctors who are part of a family
planning clinic and who perform [surgical] abortions and
who have the expertise in the field to be able to prescribe the
abortion pill. However, in my community, there is a doctor [a
family physician] who does a lot of obstetrics, and who, for
me, with a specific training on this subject, would perhaps be
a good person to prescribe the abortion pill… » (QC-NTNP-
4). Several participants did not understand who was
allowed to prescribe MIFE-MISO. These policies deterred
them from providing MTOP, in particular because of the
length of the mandatory clinical training. Some participants
had the impression that these policies were meant to slow
down the implementation of MTOP. Participants felt there
were too many regulations regarding this new medication.
As one participant expressed: ‘We must not exaggerate the
Table 3. Classification of participants at baseline according to the five stages of change [12].
Stages of change N Profession
Completed
SOGC
training
Know
of SOGC
training
Provision
of T1MA
Provision
surgical
abortion
Offer
MIFE-MISO
T1MA Intention
Preparation
of material
Does offer MIFE-MIS0 T1MA
Maintenance 3 FP: 3 1 3 3 3 3 N/A N/A
Do Not Offer MIFE MISO T1MA
Action 2 OB: 2 2 2 2 2 Ready: 2
Preparation 5 FP: 2
OB: 3
4 5 1 5 5 Ongoing:3
Potential: 2
Advanced Contemplation 8 FP: 4
OB: 4
7 1 2 8 Potential: 6
Slow Contemplation 12 FP: 11
OB: 1
5 2
Not sure: 10
Pre-Contemplation 7 FP: 5
OB: 2
3 2
Legend:
- Profession: Family physician (FP), Obstetrician-gynaecologist (OB).
- Completed SOGC training: value¼ those who have completed the SOGC T1MA training programme, cells with no value¼ those who have not.
- Know of SOGC training: value¼ those who are aware of the SOGC T1MA training programme, cells with no value¼ those who are not.
- Provision of T1MA: value¼ those who actually provide 1rst trimester MA, cells with no value¼ those who do not.
- Provision of surgical abortion: value¼ those who actually provide SA, cells with no value¼ those who do not.
- Offer MIFE-MISO T1MA: value¼ those who offer MIFE-MISO T1MA at the time of interview, cells with no value¼ those who have not.
- Intention: value¼ those who have the intention to offer MIFE-MISO MA services, Not sure¼ those who were not sure of their intention to offer MIFE-
MISO services, cells with no value¼ those who have not.
- Preparation of material: ready¼ those whose material is ready for starting MIFE-MISO T1MA practice, ongoing¼ those whose material is being prepared
for starting MIFE-MISO T1MA practice, potential¼ those who are thinking on what material to prepare, cells with no value¼ those who are not thinking
nor preparing any material.
- N/A: Not applicable.
Table 4. Facilitators according to the five stages of change [12].
Facilitators Stages of change Examples of quote
Influence or support
of colleagues
All stages ‘ … we met, as a team, so the nurse who is the head nurse at the Centre de
consultation des femmes with the managers all that, so we met and we are
making prototypes, creating protocols so that it can be done, we wanted
that before implementing it that it be really good, that we have a protocol
and that the rules of use are clear and, but that’s it, we’re in the process of
making protocols…’ (QC-TNP-3) (PREPARATION)
Request of patients
or colleagues
All stages ‘ A week or two ago, I dealth with a family doctor who was approached by a
patient, a family doctor who is in X but does not provide abortions, who
was approached by a patient because she absolutely wanted this pill and
she was disappointed to know that it was not available at our place. ‘ (QC-
NTNP-17) (PRE-CONTEMPLATION)
Awareness of research
or study
All stages but the slow
Contemplation stage
‘ … mifepristone, I used it in the context of two or three studies…’ (QC-NTP-
16) (MAINTENANCE)
Interest for a
new practice
Maintenance, Action and Slow
Contemplation stages
‘ … it might also be a reason to change a little bit the way we do things
here.’ (QC-NTP-3) (ACTION)
Facilitators are presented in order of importance, i.e., number of participants mentioning this facilitator. Previous experience is also a facilitator but, in this
article, it is treated as a basic characteristic of participants.
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regulation of it to make it more complicated and thus, it will
become inaccessible.’ (QC-NTNP-10)
Other barriers
The availability and close proximity of surgical TOP services
was one of the most reported barrier for participants in the
Pre-Contemplation stage. Participants in the Slow
Contemplation and Pre-Contemplation stages also men-
tioned lack of information and experience in MTOP practice,
low requests for TOP, uncertainty about future practice and
ethical concerns. Some physicians, especially those working
in TOP clinics, worried about the involvement of primary
care professionals and thought that: ‘ … many doctors, at
least amongst the colleagues we know who do not work in
family planning clinics, even if they work a lot in women’s
health, they are not used to doing these things [TOPs].’ (QC-
TP-2) Another physician also mentioned that it existed:’… a
culture that was in favour of surgical abortion and that
claimed that medical abortion meant bleeding a lot, and
hurting a lot …’ (QC-NTP-16), and this attitude meant that
workers in TOP clinics ‘ … weren’t so eager to have access to
mifepristone or to offer abortion by medication. We didn’t feel
it was a priority’ (QC-NTP-16) Some physicians expressed
concerns because of perceived additional counselling and
required reorganisation for clinic functioning: ‘… what
raises questions for me is the length of time it takes to explain
to the patient … How are we going to get around it with the
patient, and the nurses are included in that …’ (QC-NTNP-15)
In addition, a financial impact on the provider income was
underlined by some who declared that ‘… some big, big,
big surgical abortion clinics probably didn’t like it [MIFE-MISO
T1 MTOP] much either… Because there are people whose
livelihood depends on doing curettages…’ (QC-NTP-3)
Follow-up behaviour
The number of physicians in our sample who provided
MIFE-MISO T1 MTOP one year after baseline interviews
Table 5. Principal barriers according to the five stages of change [12].
Barriers Stages of change Examples of quote
Complexity of local health care
organisation
All stages ‘ It’s the big health organisation machine that seems to me to be an
obstacle there, because it’s slow, everything is slow, we ask for
something there, well we go to a meeting, instead of being every three
months, our meetings are every six months because there is no way to
plan them, and then when we come back there, nothing has
advanced… Then, the Minister does not have an umbilical cord with
our health organisation, so we do not know… Things are stagnating
there, it makes it frustrating. ‘ (QC-TNP-1) (PREPARATION)
Lack of local resources or
support of colleagues
Preparation, Contemplation
(advanced and slow), Pre-
Contemplation stages
‘ … we have not secretarial services, no services, we are not equipped at
our abortion clinic, we have no telephone operator, we have no
receptionist to schedule appointments, to do telephone evaluations,
because otherwise it is nurses and the social worker who do that, we
have no secretary, we have not computer service to transcribe, if there
are Excel files to edit, we have no one for us, so that’s an obstacle for
us… ’ (QC-NTNP-2) (SLOW CONTEMPLATION)
Uncertainty/confusion re:
practice policies
All stages ‘ … I’ve been confused in the last weeks about the information I’ve
received from several different involved parties, it means that, yes, it’s
actually a barrier there… it would have to be clearer in terms of
training, what we really need to do, and you know, clearer in terms of
who can really prescribe the abortion pill, is it just doctors of family
planning clinics, or if it’s more people, it would have to be clarified…’.
(QC-NTNP-4) (ADVANCED CONTEMPLATION)
Uncertainty re: collaboration of
personnel and colleagues
Preparation, Contemplation
(advanced and slow), Pre-
Contemplation stages
‘ My colleague had been alone at the Family Planning Clinic for five years,
and she often asked that there be a gynaecologist from time to time
who could come and do abortions, if she was less available or if there
were more requests. And the gynaecologist team didn’t want to get on
board until now, so I know that she was a little apprehensive about
talking to them about [the abortion pill] to see if they were going to
get on board or not, since her other attempts in recent years hadn’t
been successful…’ (QC-NTNP-24) (ADVANCED CONTEMPLATION)
Uncertainty re: lack of
information and experience
in the practice
Preparation, Contemplation
(advanced and slow), Pre-
Contemplation stages
‘ I have no idea how to deal with [MA]… how to do the abortion, the
management, the follow-up with the abortion pill… It hasn’t broken
through in my environment, so it’s not something that’s easy to start or
initiate because we don’t even have the information. It’s not really
getting to us…’ (QC-NTNP-27) (SLOW CONTEMPLATION)
Abortion services
available nearby
Contemplation (advanced and
slow), Pre-
Contemplation stages
‘ What prevents me from giving it is precisely an easy access to people
who have an interest in this field and for whom it’s easy… an
accessibility that is easy for me. So it’s more something that I have
than something we don’t have that’s going to keep me from getting
into this. ‘ (QC-NTNP-28) (PRE-CONTEMPLATION)
Uncertainty re: people
involved or could be
involved in this practice
Maintenance, Contemplation
(advanced and slow), Pre-
Contemplation stages
‘ Right now, the people I work with are not exhausted, but let’s say they’re
aging. So you know, I think the problem we’re going to have eventually
if it stays as it is now at the government and management level in
relation to doctors’ practices is that we’re going to have a problem
eventually to have doctors working on abortions. ‘ (QC-TP-2)
(MAINTENANCE)
Uncertainty re: organisational
flexibility to provide
this service
All stages ‘ … how do we keep it confidential when we don’t have an abortion clinic
and we have a clinic where at the same time as abortion there are also
patients who come for all kind of other reasons… and to keep
discussions confidential… and consent can be difficult in our
communities right now… ‘QC-TNP-4 (PREPARATION)
Barriers are presented in order of importance, i.e., number of participants mentioning this barrier.
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tripled (n¼ 10) (Table 6) (response rate ¼ 97%). Most of
the new prescribers (5 out of 7) were in the Action and
Preparation stages the year before, and were already pro-
viders of T1 MTOP and surgical (n¼ 2) or surgical TOP only
(n¼ 3). Two new prescribers from the Slow Contemplation
stage also started: one had experience in surgical TOP and
the other provided patient assessment in a TOP clinic. All
physicians in the Preparation stage who did not start and
most participants in the Advanced Contemplation stage
still intended to start. The majority of participants in the
Slow Contemplation stage and all participants in the Pre-
Contemplation stage either abandoned their intention or
never intended to start since baseline. Seven of 16 partici-
pants (44%) who worked in TOP clinics at baseline were
still not providing MIFE-MISO T1 MTOP one year later.
Participants who were providing MIFE-MISO T1 MTOP at
one-year follow-up were almost equally FP (n¼ 7/25;28%)
and OB (n¼ 3/12;25%). Compared to those who did not,
participants who were providing MIFE-MISO T1 MTOP at
one year had completed the online MTOP training at base-
line (40% versus 4%; p¼ 0.004); were working in TOP clinics
(90% versus 35%; p¼ 0.006); were already offering T1
MTOP (50% versus 15%; p¼ 0.026) or surgical TOP (80%
versus 33%; p¼ 0.011). The number of MIFE-MISO T1 MTOP
performed by these participants varied from 3 to 50 during
the initial year.
Discussion
This study shows that, in spite of a positive non stigma-
tised cultural context and a strong infrastructure of TOP
clinics, implementation of MIFE-MISO T1 MTOP in Quebec
was slow and laborious. Interestingly, Quebec has a public
drug insurance plan that fully reimburses prescription med-
ications for residents of Quebec, including MIFE-MISO,
which was in place before the launch of the product. Also,
to provide T1 MTOP, Quebec physicians have a remuner-
ation equal to T1 surgical TOP or are paid on a salary basis.
Nevertheless, more health system support appears needed
to enable primary care physicians to provide MIFE-MISO
in Quebec.
Complexity of local health care organisations was the
most commonly mentioned barrier to implementation by
all participants whatever their stage of change. Such
administrative barriers were also seen at the time of MIFE-
MISO introduction in England and Wales where some hos-
pitals gave low priority to TOP services, and bureaucratic
inertia discouraged providers from adopting this new prac-
tice [19]. In Australia, where, like Canada, MIFE-MISO was
recently approved as a subsidised medicine provided by
primary care professionals, institutional capacities, such as
lack of a distinct TOP service system, absence of telephone
or Internet service to inform patients about TOP facilities
and lack of accountability in ensuring local service delivery
were reported as key barriers to implementation [20].
Understanding the local context in which implementation
takes place is a preliminary step when beginning a new
practice; too much perceived local complexity may discour-
age those with limited motivation [12].
Lack of human and/or material resources, lack of sup-
port from colleagues and uncertainty about collaboration,
primarily reported by participants in the Preparation and
Contemplation stages, echo findings of Doran and
Nancarrow [21] as well as those of Furedi of the British
Pregnancy Advisory Service stating that staff support is the
«absolute single main driver» explaining mifepristone use
across providers [19]. As mentioned by participants work-
ing in Quebec TOP clinics, difficulties maintaining or
recruiting medical staff appeared linked to recent Quebec
governmental policy promoting a family physician (FP) for
every citizen [22]. This policy requires FP to register at least
500 patients in their clientele and financial incentives are
given to register more; therefore, they have limited time or
interest to join existing TOP teams or engage in new prac-
tices. Similarly, in Australia, the need for partnerships or
other collegial arrangements was cited in connection with
busy workloads or stigma [20].
As shown in many countries, legal constraints are very
influential on access to TOP services [19,23]. Health Canada
had removed all restrictions to MIFE-MISO combination use
as of April 2019 (Table 1) [9,24]. Yet, the CMQ still requires
several of the removed restrictions such as mandatory
ultrasound dating, clinical training in TOP before providing
MIFE-MISO and no authorisation for nurse practitioners to
Table 6. Classification of participants at one-year follow-up according to the five stages of change [12].
Stages of change
BASELINE 1-YEAR FOLLOW-UP
N
Offer MIFE-
MISO T1MA Intention
Offer MIFE-MISO
T1MA
Yes
Intention of those
who do not offer
Yes
Average number of
MIFE-MISO T1MA
during the past
year
(range of 3 to 50)
Maintenance 3 3 3 N/A 27
Action 2 2 2 N/A 6
Preparation 5 5 3 2 18
Advanced
Contemplation
8 8 0 5 0
Slow Contemplation 12 2
Not sure : 10
2 2 12
Pre-Contemplation 7 0 0 0
Legend:
- Offer MIFE-MISO T1MA at baseline: Value¼ those who offer MIFE-MISO T1MA at the time of interview; cells with no value¼ Those who do not.
- Intention at baseline: Value¼ those who have the intention to offer MIFE-MISO T1MA services, Not sure¼ those who are not sure to offer MIFE-MISO
T1MA services), cells with no value¼ those who do not.
- Mean number of MIFE-MISO T1MA: mean number of MIFE-MISO T1MA performed by participant who responded they offer MIFE-MISO T1MA at the 1-
year follow-up.
- : Missing data for one participant.
- N/A: Not applicable.
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provide MIFE-MISO without physician’s supervision of
physicians trained to provide MTOP (Table 1) [11,25]. The
CMQ also tightly regulates telemedicine which could other-
wise be used in T1 MTOP [26]. Quebec, while being very
supportive of TOP access [5], is not the only area in the
world where restrictions are notable. In the United States
(US), in 2019, where 21 states were hostile or very hostile
to TOP rights [27], state policies imposed mandatory
delays, need for in-person counselling, mandatory ultra-
sound, performance of MTOP by a licenced physician only,
and prohibition of telemedicine use to provide MTOP
[26,27]. Yet, the report of the National Academies of
Sciences, Engineering and Medicine of the United States
[28], like the publications and guidelines of many leading
organisations [29–31], reaffirmed that: T1 MTOP is in the
scope of family medicine; it can be provided without ultra-
sound dating but with appropriate medical history and
gynecological examination [32–34]; trained nurse practi-
tioners and physician assistants can provide T1 MTOP as
safely and efficiently as physicians [35]; and it can be pro-
vided through telemedicine [36,37].
One year after the baseline interview, as predicted by
the TTM approach, most participants who were in the
Action or Preparation stages started providing T1 MTOP.
Interestingly, 90% of them were already working in public
TOP clinics. In this regard, they were already aligned with
CMQ requirements and thus, had already overcome a
major barrier reported by physicians who did not work in
such settings. Nevertheless, 44% of participants working in
TOP clinics still did not provide MIFE-MISO one year after
baseline, illustrating how barriers may exist in a sensitive
field monopolised by those who perform surgical TOPs.
Communication with the director of the Federation
Quebecoise du planning des naissances, a Quebec feminist
organisation monitoring TOP services, indicated that, in
April 2019, 23/49 public TOP clinics, mostly located in rural
areas, were still not providing MIFE-MISO T1 MTOP [38].
The average number of MIFE-MISO T1 MTOPs provided by
our participants did not exceed 27 MTOPs. This low num-
ber was corroborated by market shares of MIFE-MISO in
2017–2018 [39] and 2017 termination data showing that
during the first year of access, MTOP represented approxi-
mately 9% of all TOPs in Quebec [40] compared to 30% or
greater in Ontario and British Columbia [16]. As shown in a
2017 worldwide review [23], the proportion of all TOPs that
were MTOP increased in most countries (proportions up to
59% in France and to 80% to 90% in Sweden and Finland).
At the time of mifepristone introduction in Sweden, TOP
providers’ receptiveness to provide MTOP depended mostly
on the interest of a particular facility’s head and staff [19].
In Great Britain, local medical culture supporting MTOP was
also very influential on providers’ uptake of this practice
[19]. On the contrary, the pace of increase was slow in
Belgium, Germany, Italy and the Netherlands; MTOP repre-
sented less than 25% of all TOPs in these countries [23]. In
the US [41], 14 years after mifepristone’s approval, 23% of
all TOPs were MTOPs. The predominance of surgical TOP in
these countries, as in Quebec, was mainly due to restrictive
policies, bureaucratic restrictions and preferences among
providers or women for surgical TOP [23].
We acknowledge limitations to this study such as a
plausible desirability bias and participating in this research
being a catalyst to engage in MTOP practice. Since this
study was performed at the very beginning of the availabil-
ity of MIFE-MISO in Quebec, it may have elicited more bar-
riers than facilitators. Our follow-up survey was just
designed to capture adoption of the new behaviour one
year later and thus, was too brief to describe further facili-
tators and barriers to the provision of MIFE-MISO. Strengths
of our study included a robust sample of 37 participants,
representing all Quebec Health regions, through various
recruitment strategies, and a theory-informed study and
interview guide.
This study highlights several barriers to MIFE-MISO T1
MTOP implementation including additional regulatory
restrictions imposed by a provincial jurisdiction, despite
strong scientific evidence and Health Canada’s support of
its full accessibility in primary care. The province of Quebec
is one example where additional regulatory restrictions are
imposed by the medical regulatory body [28]. These med-
ical policy restrictions act as a bottleneck to the resolution
of other bureaucratic and system barriers. Potential ave-
nues that could improve implementation of MIFE-MISO T1
MTOP in Quebec include enhancing physicians’ and nurse
practitioners’ MTOP training, increasing perceived ease of
MTOP, emphasising integration of MTOP training in family
medicine residency programmes, consolidating surgical
TOP clinics with provision of additional services such as
treatment of first trimester pregnancy failures, reducing
logistical barriers, fostering professional collaboration, and
doing research on Quebec women’s attitude towards med-
ical versus surgical TOPs as well as on nurses’ roles, needs
and experiences regarding MTOP. Until barriers are
addressed and strategies to support uptake of MTOP are
implemented, access and choice for individuals in Quebec
seeking safe and effective MTOP will continue to
be hindered.
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